Efficacy of Azvudine Therapy in Patients with Severe and Non-Severe COVID‐19: A Propensity Score-Matched Analysis
Open Access
- 1 October 2024
- journal article
- research article
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 17, 4317-4325
Abstract
Objective: Azvudine is used to treat patients with the coronavirus disease 2019 (COVID-19). This study evaluated the clinical efficacy of azvudine in hospitalized patients with different severities of COVID-19 because few studies have described this in patients with severe and non-severe COVID-19. Methods: This retrospective study included hospitalized patients with COVID-19 in Guizhou Provincial People’s Hospital between December 2022 and January 2023. Azvudine-treated patients and controls were matched for sex, age, and disease severity at admission. Laboratory results and outcomes, including all-cause mortality, invasive mechanical ventilation, intensive care unit admission, and hospital stay length, were evaluated. Stratified analysis was used to explore the difference in the efficacy of azvudine in severe and non-severe COVID-19 patients. Results: No significant differences in all-cause mortality were observed between the 303 azvudine recipients and 303 matched controls. However, azvudine-treated patients had shorter hospital stays (8.34± 4.79 vs 9.17± 6.25 days, P=0.046) and higher lymphocyte improvement rates (21.5% vs 13.9%, P=0.019), with a more pronounced effect in patients with non-severe COVID-19 (length of hospital stay, 8.07± 4.35 vs 10.00± 6.29 days, P=0.001; lymphocyte improvement rate, 23.8% vs 12.8%, P=0.015). Conclusion: Azvudine treatment shortens hospital stay length and increases the rate of lymphocyte count improvement in patients with non-severe COVID-19, suggesting that azvudine may be a treatment option for these patients.Keywords
This publication has 38 references indexed in Scilit:
- Cost-effectiveness of Azvudine for High-risk Outpatients with Mild-to-moderate Coronavirus Disease 2019 in ChinaClinical Therapeutics, 2024
- Real-world effectiveness of molnupiravir, azvudine and paxlovid against mortality and viral clearance among hospitalized patients with COVID-19 infection during the omicron wave in China: A retrospective cohort studyDiagnostic Microbiology and Infectious Disease, 2024
- Selectively T cell phosphorylation activation of azvudine in the thymus tissue with immune protection effectActa Pharmaceutica Sinica B, 2024
- Azvudine therapy of common COVID‐19 in hemodialysis patientsJournal of Medical Virology, 2023
- Oral azvudine for mild‐to‐moderate COVID‐19 in high risk, nonhospitalized adults: Results of a real‐world studyJournal of Medical Virology, 2023
- Bench-to-bedside: Innovation of small molecule anti-SARS-CoV-2 drugs in ChinaEuropean Journal of Medicinal Chemistry, 2023
- Oral Azvudine for hospitalised patients with COVID-19 and pre-existing conditions: a retrospective cohort studyeClinicalMedicine, 2023
- A Randomized, Open‐Label, Controlled Clinical Trial of Azvudine Tablets in the Treatment of Mild and Common COVID‐19, a Pilot StudyAdvanced Science, 2020
- Hematological findings and complications of COVID‐19American Journal of Hematology, 2020
- Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, ChinaJAMA, 2020